SCHEMBL21982018

SCHEMBL21982018

CC(C)CCCNCCCCNCC(C)CCCNCCCN

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.48
CA2 P00918 3/20 0.48
CA4 P22748 3/20 0.48
CA6 P23280 3/20 0.48
CA5A P35218 3/20 0.48
CA7 P43166 3/20 0.48
CA9 Q16790 3/20 0.48
CA14 Q9ULX7 3/20 0.48
CA5B Q9Y2D0 3/20 0.48
F13A1 P00488 2/20 0.48
CYP1A2 P05177 2/20 0.48
ALOX15 P16050 2/20 0.48
THPO P40225 2/20 0.48
CASP2 P42575 2/20 0.48
MEN1 O00255 1/20 0.48
CYP2C19 P33261 1/20 0.48
RECQL P46063 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CA3 P07451 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2107512 0.92 CA12 (0.50) CA12CA2CA4CA6CA5A
SCHEMBL24175702 0.91 LMNA (0.43) CA12CA2CA4CA6CA5A
SCHEMBL18471052 0.91 LMNA (0.43) CA12CA2CA4CA6CA5A
SCHEMBL7587571 0.88 LMNA (0.46) ALOX15MEN1CYP2C19KMT2ATSHR
SCHEMBL13501914 0.88 CA12 (0.62) CA12CA2CA4CA6CA5A
SCHEMBL30292581 0.86 CA12 (0.46) CA12CA2CA4CA6CA5A
SCHEMBL12335787 0.86 CA12 (0.57) CA12CA2CA4CA6CA5A
SCHEMBL21164243 0.85 CA12 (0.43) CA12CA2CA4CA6CA5A
SCHEMBL14413917 0.84 CA12 (0.50) CA12CA2CA4CA6CA5A
SCHEMBL8863209 0.84 CA12 (0.48) CA12CA2CA4CA6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy THE JOHNS HOPKINS UNIVERSITY (US) 2023-07-11 US disclosed
US-20200140831-A1 TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY THE JOHNS HOPKINS UNIVERSITY 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy POLRMT, HDGF, PCNP CA12 1062/4885CA2 3727/4885CA4 2682/4885
US-20200140831-A1 TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY POLRMT, HDGF, PCNP CA12 1062/4885CA2 3727/4885CA4 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.